Navigation Links
Karen Walton-Bowen Joins Abt Bio-Pharma Solutions, Inc., as Senior Director, Biometrics
Date:10/22/2008

CAMBRIDGE, Mass., Oct. 22 /PRNewswire/ -- Karen Walton-Bowen, M.Sc., C.Stat, a biostatistician with more than 20 years experience in the pharmaceutical and biotechnology industries, has joined Abt Bio-Pharma Solutions, Inc. (ABS), as Senior Director, Biometrics. An expert in clinical trials and regulatory submissions in all phases of clinical development across multiple therapeutic areas, Ms. Walton-Bowen's experience encompasses clinical operations, data management, programming, statistical support, and medical writing, both in the U.S. and in Europe. In addition to leading ABS' full service Biometrics team, she will work one-on-one with sponsors to provide sophisticated biostatistics and medical writing consulting services for registries and late-phase clinical trials.

"Karen's strong technical and project management skills will make her a 'go to' resource for our small- to medium-size clients who wish to extend their capabilities with direct access to an hands-on expert with broad and deep therapeutic area experience," said Dr. Kay Larholt, Vice President of Biometrics & Clinical Operations. "We also expect Karen to add value and strengthen our already accomplished Biometrics team as it continues to support all our clinical projects, including clinical trials and registries."

Prior to joining ABS, Ms. Walton-Bowen was most recently Senior Director of Clinical Operations, Biostatistical Analysis, and Reporting at Critical Therapeutics, Inc. Previously, she spent four years at Genzyme Corporation, where she led the Biometrics team in a successful BLA submission and FDA Advisory Panel approval of a drug for a rare life-threatening disease in children. Ms. Walton-Bowen also spent many years at Astra (in the US and Sweden) as a biostatistician working on different compounds in the respiratory business unit. During that time she submitted numerous NDAs and represented the company at FDA meetings and Advisory Panels.

Ms. Walton-Bowen was awarded her M.Sc. in Medical Statistics by the University of London and earned her B.S. degree with honors in Mathematics & Computing from South Bank University, London, England. She is a member of the Royal Statistical Society, American Statistical Association, Drug Information Association, and the Association of Clinical Research Professionals. Ms. Walton-Bowen's work has been published in leading journals including Statistics In Medicine, The Journal of Pediatrics, and Annals of Allergy, Asthma & Immunology. She was also a contributor to Biopharmaceutical Sequential Statistical Applications, an important textbook on interim analyses with contributions from industry leaders.

The ABS team has provided integrated strategic, research, and commercialization services to the pharmaceutical, biotechnology, medical device, and diagnostics industries for more than 20 years. The company specializes in demonstrating the value, safety, and efficacy of health technologies through prospective studies such as registries as well as through retrospective data analyses, models, and quantitative and qualitative research. ABS teams of senior, seasoned staff help sponsors develop their research agendas, successfully conduct their research programs, and communicate the results to internal and external audiences. Primary service offerings include biometrics, clinical trials, registries and other late-phase clinical studies, health economics and outcomes research, pricing and reimbursement, and strategic commercialization services. Previously known as Abt Associates Clinical Trials, the company was renamed Abt Bio-Pharma Solutions and established as a wholly owned subsidiary of Abt Associates in April 2008.


'/>"/>
SOURCE Abt Bio-Pharma Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Health Monitoring Systems Appoints Karen S. Dockrell As VP, Sales
2. Food and Beverage Giant Joins Kannapolis Research Center
3. Mark Sutherland Joins GenVault as Senior Vice President, Business Development
4. Chief Technology Officer Joins ACAMP
5. Charles C. Harwood, Jr., Joins Cellectar, Inc.s Board of Directors
6. Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines
7. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
8. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
9. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
10. GM Exec Joins Bio-Reaction Industries Board of Directors
11. Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is ... and 8th June 2018 in San Francisco, CA. The Summit brings together current and ... distinguished CEOs, board directors and government officials from around the world to address key ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
Breaking Biology News(10 mins):